Argenx Se (ARGX) Current Deferred Revenue (2015 - 2020)
Argenx Se (ARGX) posted quarterly Current Deferred Revenue of $292.5 million for Q4 2020, down 11.49% year-on-year from $330.4 million in Q1 2020, and up 281.91% on a QoQ basis from $76.6 million in Q2 2020.
Argenx Se (ARGX) Current Deferred Revenue (2015 - 2020) Analysis & Trends
Argenx Se (ARGX) has reported Current Deferred Revenue for 6 consecutive years, with $292.5 million the latest figure, recorded in Q4 2020.
- Quarterly Current Deferred Revenue fell 11.49% year-over-year to $292.5 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $292.5 million (down 11.49% YoY) and the FY2020 annual result came in at $46.3 million, down 42.99% from the prior year.
- Current Deferred Revenue grew to $292.5 million in Q4 2020 per ARGX's latest filing, from $76.6 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for ARGX reached as high as $330.4 million in Q4 2019 and fell as low as $2.5 million in Q4 2018.
- A 5-year average of $93.3 million and a median of $31.1 million in 2017 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2018 — Current Deferred Revenue slumped 86.6% — and 2019, when it jumped 13336.88%.
- Year by year, Current Deferred Revenue stood at $29.1 million in 2016, then plunged by 36.83% to $18.4 million in 2017, then sank by 86.6% to $2.5 million in 2018, then soared by 13336.88% to $330.4 million in 2019, then decreased by 11.49% to $292.5 million in 2020.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $292.5 million, $76.6 million, and $330.4 million for Q4 2020, Q2 2020, and Q4 2019 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 292.46 Mn |
| Jun 30, 2020 | 76.58 Mn |
| Dec 31, 2019 | 330.43 Mn |
| Jun 30, 2019 | 52.19 Mn |
| Dec 31, 2018 | 2.46 Mn |
| Jun 30, 2018 | 7.09 Mn |
| Dec 31, 2017 | 18.36 Mn |
| Jun 30, 2017 | 31.13 Mn |
| Dec 31, 2016 | 29.06 Mn |
| Dec 31, 2015 | 5.98 Mn |